Oak Hill Capital Acquires Majority Stake in Technimark Holdings LLC

Oak Hill Capital (“Oak Hill“), a New York-based middle-market private equity firm, announced that it had agreed to acquire a controlling stake in Technimark Holdings LLC (“Technimark” or “the Company”) through Oak Hill’s fifth institutional fund, forming a partnership with current investors, Pritzker Private Capital (“PPC”) and management. The terms of the transaction were not disclosed.

Headquartered in Asheboro, North Carolina, Technimark is a leading designer and manufacturer of custom, highly-engineered injection molded components, which it sells to a group of global healthcare, consumer and specialty industrial customers. “We have a great deal of respect for what Technimark has accomplished, including its strong track-record of delivering industry leading quality and service to its customers,” said Brian Cherry, Managing Partner at Oak Hill. “We are delighted to partner with Technimark’s world class management team.”

“Technimark is a fantastic business with industry leading engineering and innovation capabilities and a very impressive list of global customers,” said John Rachwalski, a Partner at Oak Hill. “Thanks to strong leadership and smart, well-executed investments, Technimark is distinctively positioned to capitalize on the trends in its core target markets. We look forward to supporting the Company’s exciting growth agenda over the course of our partnership.”

The management team of Technimark, led by Chief Executive Officer Brad Wellington, will continue to lead the Company and retain a meaningful ownership stake. “Oak Hill is a firm that shares our collaborative culture and our growth vision for the business. We look forward to a successful partnership as we continue investing in Technimark’s manufacturing and innovation capabilities to drive best-in-class results for our customers,” said Wellington.

William Blair & Company served as financial advisor to Oak Hill on the transaction and Goldman Sachs & Co and Wells Fargo Securities, LLC acted as financial advisor to Technimark. Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisor to Oak Hill and Kirkland & Ellis LLP is serving as legal counsel to Technimark and PPC.

The transaction is expected to close in the third quarter of 2021 and represents the ninth investment in the Oak Hill Capital Partners V portfolio.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”